Skip to main content

An unnamed worker waters cannabis plants on Steve Dillon's farm in Humboldt County, Calif. on Aug. 28.

STAFF/REUTERS

A bevy of state ballot measures passed this week reveal it's only a matter of time before legalized marijuana use is the law of the land in the U.S. Investors are already finding ways to buy into it.

Four states voted on Tuesday to legalize recreational pot use, while four others approved marijuana for medicinal purposes. That brings the number of Americans living in states where recreational marijuana is legal up to 20 per cent of the U.S. population. That percentage rises to 58 percent and 66 per cent of the U.S. population when counting states where medical marijuana is legal and where states have decriminalized the drug, respectively.

Federal legalization of recreational marijuana use is probably not around the corner. But that's almost beside the point. States are following their own course, and will likely be even more emboldened once states-rights advocates move into the White House, the Senate, and the House of Representatives.

Story continues below advertisement

It also doesn't hurt that President-elect Donald Trump has touted his support of medical marijuana - although his constantly shifting views on just about everything, along with Vice President-elect Mike Pence's opposition to marijuana, cloud that stance. Perhaps that's why a Bloomberg Intelligence index of 32 public companies involved in cannabis-related products fell 7 percent on Tuesday.

Still, despite that drop - which was concentrated in three pharma companies - the index is up 181 per cent year-to-date.

Besides companies directly related to the production of cannabis, many of which are characterized as pharma firms, plenty of other businesses stand to benefit.

For one, you can bet big tobacco giants R.J. Reynolds Tobacco Co., Altria Group Inc., and Philip Morris International Inc. are not standing still here. As one top tobacco executive told me last March, these companies already know how to make money in the tightly regulated industry of cigarettes, and marijuana will be no different.

It's no secret e-cigarettes and products that heat tobacco rather than burn it are also used by marijuana smokers. My colleague Tara Lachapelle points out there's $45-billion in potential annual demand for recreational weed in the U.S., and the tobacco companies are a perfect fit to serve this market.

Then there are companies such as The Scotts Miracle-Gro Co., which benefit from growing marijuana. In the past 18 months Scotts has been on a buying spree of companies that make fertilizers, lighting and other supplies for growers. The company's hydroponics business now brings in $250-million in annual sales. Also benefiting are home-and-garden retailers and hardware stores such as Home Depot Inc. and True Value Co., whose sales in this area have skyrocketed in the past year.

To find the other side of this trade, look for companies spending big bucks to oppose pot legalization. The alcohol industry, for example, worries that making marijuana more available will make people drink less alcohol, Bloomberg News's Jennifer Kaplan points out. Sam Adams brewer Boston Beer Co. and Jack Daniel's exporter Brown-Forman Corp. are among those that call legal weed a threat to their companies.

Story continues below advertisement

Pharmaceutical companies, fearing competition for their anti-anxiety and other drugs, have also funded anti-pot measures. One painkiller producer, Insys Therapeutics, scored a victory on Tuesday as Arizona voted down a measure to legalize recreational marijuana. Medical marijuana has been legal in that state since 1996.

Nevertheless, if Tuesday's election taught us anything, it's that America is changing, as are truths that some take for granted. Legalizing marijuana is no different.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter